1-5 of 5
Bertrand Coiffier
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study

Sydney Dubois, Pierre-Julien Viailly, Sylvain Mareschal, Elodie Bohers, Philippe Bertrand, Philippe Ruminy, Catherine Maingonnat, Jean-Philippe Jais, Pauline Peyrouze, Martin Figeac, Thierry J. Molina, Fabienne Desmots, Thierry Fest, Corinne Haioun, Thierry Lamy, Christiane Copie-Bergman, Josette Brière, Tony Petrella, Danielle Canioni, Bettina Fabiani, Bertrand Coiffier, Richard Delarue, Frédéric Peyrade, André Bosly, Marc André, Nicolas Ketterer, Gilles Salles, Hervé Tilly, Karen Leroy, Fabrice Jardin
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (12): 2919–2928.
https://doi.org/10.1158/1078-0432.CCR-15-2305
Published: 14 June 2016
View article titled, Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study
Open the PDF for Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study in another window
Includes: Supplementary data
Journal Articles

A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Vincent Ribrag, Jehan Dupuis, Herve Tilly, Franck Morschhauser, Fabrice Laine, Roch Houot, Corinne Haioun, Christiane Copie, Andrea Varga, John Lambert, Laurence Hatteville, Samira Ziti-Ljajic, Anne Caron, Sandrine Payrard, Bertrand Coiffier
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (1): 213–220.
https://doi.org/10.1158/1078-0432.CCR-13-0580
Published: 05 January 2014
View article titled, A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Open the PDF for A Dose-Escalation Study of SAR3419, an Anti-CD19 Antibody Maytansinoid Conjugate, Administered by Intravenous Infusion Once Weekly in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma in another window
Includes: Supplementary data
Journal Articles

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier, Weimin Li, Erin D. Henitz, Jayaprakash D. Karkera, Reyna Favis, Dana Gaffney, Alice Shapiro, Panteli Theocharous, Yusri A. Elsayed, Helgi van de Velde, Michael E. Schaffer, Evgenii A. Osmanov, Xiaonan Hong, Adriana Scheliga, Jiri Mayer, Fritz Offner, Simon Rule, Adriana Teixeira, Joanna Romejko-Jarosinska, Sven de Vos, Michael Crump, Ofer Shpilberg, Pier Luigi Zinzani, Andrew Cakana, Dixie-Lee Esseltine, George Mulligan, Deborah Ricci
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (9): 2551–2561.
https://doi.org/10.1158/1078-0432.CCR-12-3069
Published: 30 April 2013
View article titled, Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab
Open the PDF for Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab in another window
Includes: Supplementary data
Journal Articles

Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties

Clémentine Sarkozy, Bertrand Coiffier
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1660–1669.
https://doi.org/10.1158/1078-0432.CCR-12-2837
Published: 02 April 2013
View article titled, Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties
Open the PDF for Diffuse Large B-cell Lymphoma in the Elderly: A Review of Potential Difficulties in another window
Includes: Supplementary data
Journal Articles

Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: Results from a Phase II Multicenter Study

Miklos Pless, Karim Belhadj, Hans D. Menssen, Wolfgang Kern, Bertrand Coiffier, Jürgen Wolf, Richard Herrmann, Eckhard Thiel, Doug Bootle, Ivo Sklenar, Christian Müller, Les Choi, Carl Porter, Renaud Capdeville
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (4): 1299–1305.
https://doi.org/10.1158/1078-0432.CCR-0977-03
Published: 20 February 2004
View article titled, Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: <subtitle>Results from a Phase II Multicenter Study</subtitle>
Open the PDF for Clinical Efficacy, Tolerability, and Safety of SAM486A, a Novel Polyamine Biosynthesis Inhibitor, in Patients with Relapsed or Refractory Non-Hodgkin’s Lymphoma: <subtitle>Results from a Phase II Multicenter Study</subtitle> in another window